Brokers Issue Forecasts for Ardelyx FY2026 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Ardelyx in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company will earn ($0.05) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.07). The business had revenue of $74.11 million during the quarter, compared to the consensus estimate of $79.40 million. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%. Ardelyx’s revenue for the quarter was up 61.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.11) EPS.

Other analysts have also recently issued research reports about the company. Scotiabank initiated coverage on Ardelyx in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $11.00 target price on shares of Ardelyx in a report on Friday, March 7th. Citigroup dropped their price target on Ardelyx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. BTIG Research initiated coverage on Ardelyx in a report on Tuesday, March 4th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $5.50 price target on shares of Ardelyx in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.39.

Ardelyx Trading Up 0.3%

Shares of Ardelyx stock opened at $3.77 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.58 and a quick ratio of 4.31. The stock has a market capitalization of $902.47 million, a PE ratio of -23.61 and a beta of 0.59. Ardelyx has a 1-year low of $3.21 and a 1-year high of $8.06. The company’s fifty day simple moving average is $4.25 and its 200-day simple moving average is $4.93.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new stake in Ardelyx in the fourth quarter valued at $25,000. Newbridge Financial Services Group Inc. acquired a new stake in Ardelyx during the fourth quarter worth about $35,000. SBI Securities Co. Ltd. purchased a new position in Ardelyx during the fourth quarter valued at approximately $41,000. Cyndeo Wealth Partners LLC acquired a new position in Ardelyx in the first quarter valued at approximately $49,000. Finally, Quarry LP purchased a new stake in Ardelyx in the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Michael Raab sold 41,666 shares of the stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $4.59, for a total value of $191,246.94. Following the transaction, the chief executive officer now owns 1,615,587 shares in the company, valued at approximately $7,415,544.33. This represents a 2.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David M. Mott acquired 100,000 shares of the firm’s stock in a transaction on Thursday, May 15th. The shares were acquired at an average price of $3.29 per share, with a total value of $329,000.00. Following the completion of the purchase, the director now owns 2,496,871 shares in the company, valued at approximately $8,214,705.59. This trade represents a 4.17% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 166,809 shares of company stock worth $708,914 in the last three months. Corporate insiders own 4.80% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.